Logo image of TXMD

THERAPEUTICSMD INC (TXMD) Stock Fundamental Analysis

USA - NASDAQ:TXMD - US88338N2062 - Common Stock

1.08 USD
+0.01 (+0.93%)
Last: 9/29/2025, 8:12:32 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TXMD. TXMD was compared to 196 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TXMD had negative earnings in the past year.
TXMD had a positive operating cash flow in the past year.
In the past 5 years TXMD reported 4 times negative net income.
In the past 5 years TXMD reported 4 times negative operating cash flow.
TXMD Yearly Net Income VS EBIT VS OCF VS FCFTXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

TXMD's Return On Assets of -1.19% is fine compared to the rest of the industry. TXMD outperforms 77.55% of its industry peers.
TXMD's Return On Equity of -1.68% is amongst the best of the industry. TXMD outperforms 80.10% of its industry peers.
Industry RankSector Rank
ROA -1.19%
ROE -1.68%
ROIC N/A
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TXMD Yearly ROA, ROE, ROICTXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TXMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TXMD Yearly Profit, Operating, Gross MarginsTXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXMD remains at a similar level compared to 1 year ago.
TXMD has more shares outstanding than it did 5 years ago.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXMD Yearly Shares OutstandingTXMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TXMD Yearly Total Debt VS Total AssetsTXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

TXMD has an Altman-Z score of -33.83. This is a bad value and indicates that TXMD is not financially healthy and even has some risk of bankruptcy.
TXMD's Altman-Z score of -33.83 is on the low side compared to the rest of the industry. TXMD is outperformed by 86.22% of its industry peers.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -33.83
ROIC/WACCN/A
WACC9.89%
TXMD Yearly LT Debt VS Equity VS FCFTXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.89 indicates that TXMD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.89, TXMD is in line with its industry, outperforming 54.59% of the companies in the same industry.
TXMD has a Quick Ratio of 2.89. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
TXMD has a Quick ratio of 2.89. This is comparable to the rest of the industry: TXMD outperforms 56.63% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.89
TXMD Yearly Current Assets VS Current LiabilitesTXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 91.26% over the past year.
The Revenue has grown by 156.16% in the past year. This is a very strong growth!
TXMD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -48.72% yearly.
EPS 1Y (TTM)91.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.7%
Revenue 1Y (TTM)156.16%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%306.84%

3.2 Future

The Earnings Per Share is expected to decrease by -8.87% on average over the next years.
TXMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.92% yearly.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TXMD Yearly Revenue VS EstimatesTXMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TXMD Yearly EPS VS EstimatesTXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TXMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 6.23, the valuation of TXMD can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TXMD indicates a rather cheap valuation: TXMD is cheaper than 94.90% of the companies listed in the same industry.
TXMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.13.
Industry RankSector Rank
PE N/A
Fwd PE 6.23
TXMD Price Earnings VS Forward Price EarningsTXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

TXMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TXMD is cheaper than 85.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.93
EV/EBITDA N/A
TXMD Per share dataTXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

A cheap valuation may be justified as TXMD's earnings are expected to decrease with -18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%

More info and screens

0

5. Dividend

5.1 Amount

TXMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAPEUTICSMD INC

NASDAQ:TXMD (9/29/2025, 8:12:32 PM)

1.08

+0.01 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-10 2025-11-10
Inst Owners28.19%
Inst Owner Change-2.64%
Ins Owners1.55%
Ins Owner Change0.01%
Market Cap12.50M
Analysts43.33
Price TargetN/A
Short Float %0.34%
Short Ratio2.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.23
P/S 4.88
P/FCF 14.93
P/OCF 14.93
P/B 0.46
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)0.17
Fwd EY16.06%
FCF(TTM)0.07
FCFY6.7%
OCF(TTM)0.07
OCFY6.7%
SpS0.22
BVpS2.36
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.19%
ROE -1.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 32.71%
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.89
Altman-Z -33.83
F-Score7
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.7%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)156.16%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%306.84%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y53.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y100.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.65%
OCF growth 3YN/A
OCF growth 5YN/A